DaVita Inc.
HealthcareNYSE:DVA · New York Stock Exchange
+$5.85 today
Vol 0.74M · Avg 0.85M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.1B -13.8% | $1.3B +80.9% | $691.5M -11.5% | $781.6M -35.5% | $1.2B | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $715.3M -1.2% | $723.9M -2.9% | $745.4M +1.8% | $732.6M +7.6% | $680.6M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $86.6M +249.7% | -$57.8M -47.0% | -$39.4M +48.0% | -$75.7M -225.1% | $60.5M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $140.0M +36.2% | $102.8M -8.5% | $112.4M +17.8% | $95.4M -6.6% | $102.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$263.2M -782.7% | -$29.8M -115.3% | $194.5M +192508.9% | $101.0K +100.1% | -$140.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$210.6M -607.6% | -$29.8M -117.3% | $172.4M +216.2% | -$148.4M -7.4% | -$138.1M | $592.6M | $1.3B | $626.2M |
| Inventory | -$19.9M -211.2% | $17.9M +155.8% | -$32.1M -4144.6% | -$757.0K -113.2% | $5.7M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $128.3M +7451.7% | $1.7M -93.7% | $26.9M -69.3% | $87.5M +388.5% | -$30.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$161.0M -717.2% | -$19.7M -171.8% | $27.4M -55.6% | $61.8M +179.5% | $22.1M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $129.2M +299.7% | $32.3M -90.9% | $354.5M +1063.6% | $30.5M +85.2% | $16.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $1.9B -6.7% | $2.0B -1.8% | $2.1B +31.6% | $1.6B -19.0% | $1.9B | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$575.9M -3.7% | -$555.4M +2.2% | -$568.0M +5.9% | -$603.4M +5.9% | -$641.5M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 +100.0% | -$251.3M -852.0% | -$26.4M +70.4% | -$89.2M +55.6% | -$201.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$49.5M -102.2% | -$24.5M +92.4% | -$322.9M -142.1% | -$133.4M -294.2% | -$33.8M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $6.7M -75.3% | $27.2M -75.3% | $110.0M +46.9% | $74.9M +168.7% | $27.9M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$36.3M -211.7% | $32.5M -8.4% | $35.5M -70.6% | $120.8M +89.7% | $63.7M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$654.9M +15.1% | -$771.4M +0.0% | -$771.8M -22.4% | -$630.3M +19.7% | -$784.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $769.6M -30.6% | $1.1B +300.7% | -$552.6M -4799.5% | -$11.3M -101.5% | $754.3M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $23.3M +13.9% | $20.5M +21.0% | $16.9M -9.0% | $18.6M | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$1.8B -29.4% | -$1.4B -409.1% | -$272.2M +66.1% | -$802.2M +49.8% | -$1.6B | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$374.7M +33.2% | -$560.6M -54.6% | -$362.6M -11.1% | -$326.2M -36.7% | -$238.6M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$1.4B -68.3% | -$816.9M +30.2% | -$1.2B -4.4% | -$1.1B -3.5% | -$1.1B | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $21.2M +214.4% | -$18.5M -307.4% | $8.9M +130.7% | -$29.1M -190.5% | -$10.0M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$122.1M -129.4% | $415.2M +230.4% | $125.6M +158.2% | -$216.0M -506.2% | $53.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $1.3B -10.6% | $1.5B -1.6% | $1.5B +55.1% | $961.1M -25.5% | $1.3B | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.70B
Align Technology, Inc.
NASDAQ:ALGN
$12.50B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.84B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Henry Schein, Inc.
NASDAQ:HSIC
$9.30B
Universal Health Services, Inc.
NYSE:UHS
$9.19B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.68B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.71B
AptarGroup, Inc.
NYSE:ATR
$7.53B
Chemed Corporation
NYSE:CHE
$5.57B
SEC Filings
Recent regulatory filings
No filings found.
Does DVA generate free cash flow?
DaVita Inc. (DVA) generated $1.31B of free cash flow in fiscal 2025.
How much operating cash flow does DVA produce?
Operating cash flow was $1.89B, before capital expenditures of $575.86M.
Explore More
Continue the stock analysis
Jump to another research area for this company.